If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

First-line pembrolizumab “has consistent antitumor activity and safety” in patients with advanced urothelial carcinoma who are potentially ineligible for platinum‐based chemotherapy, researchers found ...

Among 9,107 mothers-to-be, those living in U.S. counties with the highest radon level (≥2 pCi/L) had a 37% greater chance of ...

The best-performing unit trusts have exposure to US tech stocks, while the laggards were invested in commodities and ...

Barclays US Consumer Bank has satisfied the city of Wilmington's three lawsuits demanding nearly $1.7M in unpaid wage taxes.

Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate ...

Industry Dominated by Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Merck KGaA, BD (Becton, Dickinson and ...

Republicans and Democrats joined together to roll out a legislative package focused on increasing access to benefits to more ...

A Code Blue emergency declaration adds another layer of urgency to the work being done by homeless outreach groups throughout ...

Seasoned advisory group including RNA, translation and commercialisation luminaries.

The market is driven by rising prevalence of several chronic disorders, rising focus on regenerative medicines, and increased federal investment in stem cell therapy.

( MENAFN - GlobeNewsWire - Nasdaq) Dublin, Jan. 10, 2025 (GLOBE NEWSWIRE) -- The "Herpes Zoster (Shingles) - Global Clinical Trials Review, 2024" clinical trials has been added to ...